Clinical Efficacy of a Soothing Dermocosmetic Cream as Adjunctive Care for Rosacea Patients Treated with Topical Ivermectine or Metronidazole.

Helena Polena¹, Arnaud Fontbonne², Pauline Chanut¹, Alexane Charreyron¹, Severine Castex¹, Sandra Trompezinski², Isabelle Benoit², Noëlle Remoué¹, Elodie VALIN¹, Bernard Cribier³, Elodie PRESTAT MARQUIS¹

¹ Naos Les Laboratoires, Bioderma, Lyon, France,

²Institut NAOS, Aix en Provence, France,

³ University Hospital of Strasbourg, Strasbourg, France

Related topics

Rosacea is a chronic inflammatory dermatosis affecting the centrofacial region in approximately 5% of adults worldwide. Tailored, individualized long-term management including dermocosmetics as adjunctive care is essential for improving skin comfort and enhancing tolerance and compliance. Efficacy and tolerance of a soothing ecobiological dermocosmetic formulation (DF) targeting innate immunity, neurogenic inflammation and skin barrier function, was evaluated alone and subsequently in combination with topical Ivermectine or Metronidazole.

Back

This page is limited to our registered members

Get access to exclusive dermatological services to increase your professionnal knowledge: +500 pathology visuals, clinical cases, expert videos
Benefit from valuable features: audio listening, materials to be shared with your patients
Stay informed about the upcoming events and webinars, latest scientific publications and product innovations

Already have an account? login now

Clinical Efficacy of a Soothing Dermocosmetic Cream as Adjunctive Care for Rosacea Patients Treated with Topical Ivermectine or Metronidazole.

Introduction

This page is limited to our registered members